Comparative effectiveness research in radiation oncology: Stereotactic radiosurgery, hypofractionation, and brachytherapy

Seminars in Radiation Oncology

Volumn 24, Issue 1, 2014, Pages 35-42

  Aneja, Sanjay ^a   Yu, James B ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; BRACHYTHERAPY; BREAST CANCER; CANCER SURVIVAL; CLINICAL TRIAL (TOPIC); COMPARATIVE EFFECTIVENESS; COMPUTER ASSISTED RADIOTHERAPY; COST EFFECTIVENESS ANALYSIS; DISEASE FREE SURVIVAL; EXTERNAL BEAM RADIOTHERAPY; HEALTH CARE COST; HUMAN; HYPOFRACTIONATED RADIOTHERAPY; INTENSITY MODULATED RADIATION THERAPY; LUNG NON SMALL CELL CANCER; MASTECTOMY; METASTASIS FREE SURVIVAL; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; PROTON THERAPY; QUALITY OF LIFE; RADIATION DOSE FRACTIONATION; RADIATION SICKNESS; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECURRENCE FREE SURVIVAL; RISK BENEFIT ANALYSIS; STEREOTACTIC RADIOSURGERY; SURVIVAL RATE;

BRACHYTHERAPY; BREAST NEOPLASMS; COMPARATIVE EFFECTIVENESS RESEARCH; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; NEOPLASMS; PROSTATIC NEOPLASMS; RADIATION ONCOLOGY; RADIOSURGERY;

EID: 84888866986     PISSN: 10534296     EISSN: 15329461     Source Type: Journal    
DOI: 10.1016/j.semradonc.2013.08.004     Document Type: Article

References (76)

1. Nguyen P.L., Gu X., Lipsitz S.R., et al: Cost implications of the rapid adoption of newer technologies for treating prostate cancer. J Clin Oncol 29:1517-1524, 2011.
2. Nygaard I. What does "FDA Approved" mean for medical devices?. Obstet Gynecol 2008, 111:4-6.
3. Katz A, Freeman D, Aronovitz J, et al: Five-year biochemical control rates for stereotactic body radiation therapy for organ-confined prostate cancer: A multi-institutional pooled analysis. Int J Radiat Oncol Biol Phys 84:S147-S148, 2012.
4. Webb S. Conformal intensity-modulated radiotherapy (IMRT) delivered by robotic linac-Testing IMRT to the limit?. Phys Med Biol 1999, 44:1639-1654.
5. King C.R., Brooks J.D., Gill H., et al. Stereotactic body radiotherapy for localized prostate cancer: Interim results of a prospective phase II clinical trial. Int J Radiat Oncol Biol Phys 2009, 73:1043-1048.
6. Freeman D.E., King C.R.: Stereotactic body radiotherapy for low-risk prostate cancer: Five-year outcomes. Radiat Oncol 6:3.
7. Chen LN, Suy S, Uhm S, et al: Stereotactic body radiation therapy (SBRT) for clinically localized prostate cancer: The Georgetown University experience. Radiat Oncol 8:58, 2013.
8. Boike T.P., Lotan Y., Cho L.C., et al. Phase I dose-escalation study of stereotactic body radiation therapy for low- and intermediate-risk prostate cancer. J Clin Oncol 2011, 29:2020-2026.
9. Jabbari S, Weinberg VK, Kaprealian T, et al: Stereotactic body radiotherapy as monotherapy or post-external beam radiotherapy boost for prostate cancer: Technique, early toxicity, and PSA response. Int J Radiat Oncol Biol Phys 82:228-234, 2012.
10. Friedland J.L., Freeman D.E., Masterson-McGary M.E., et al. Stereotactic body radiotherapy: An emerging treatment approach for localized prostate cancer. Technol Cancer Res Treat 2009, 8:387-392.
11. Katz AJ, Santoro M, Ashley R, et al: Stereotactic body radiotherapy for organ-confined prostate cancer. BMC Urol 10:1, 2010.
12. Fuller D.B., Naitoh J., Lee C., et al. Virtual HDR CyberKnife treatment for localized prostatic carcinoma: Dosimetry comparison with HDR brachytherapy and preliminary clinical observations. Int J Radiat Oncol Biol Phys 2008, 70:1588-1597.
13. Brown J.M., Koong A.C. High-dose single-fraction radiotherapy: Exploiting a new biology?. Int J Radiat Oncol Biol Phys 2008, 71:324-325.
14. Brown JM, Brenner DJ, Carlson DJ: Dose escalation, not "new biology," can account for the efficacy of stereotactic body radiation therapy with non-small cell lung cancer. Int J Radiat Oncol Biol Phys 85:1159-1160, 2013.
15. Oermann EK, Slack RS, Hanscom HN, et al: A pilot study of intensity modulated radiation therapy with hypofractionated stereotactic body radiation therapy (SBRT) boost in the treatment of intermediate- to high-risk prostate cancer. Technol Cancer Res Treat 9:453-462, 2010.
16. Zelefsky M.J., Chan H., Hunt M., et al. Long-term outcome of high dose intensity modulated radiation therapy for patients with clinically localized prostate cancer. J Urol 2006, 176:1415-1419.
17. McBride S.M., Wong D.S., Dombrowski J.J., et al. Hypofractionated stereotactic body radiotherapy in low-risk prostate adenocarcinoma: Preliminary results of a multi-institutional phase 1 feasibility trial. Cancer 2011, 118:3681-3690.
18. Kuban D.A., Tucker S.L., Dong L., et al. Long-term results of the M. D. Anderson randomized dose-escalation trial for prostate cancer. Int J Radiat Oncol Biol Phys 2008, 70:67-74.
19. Zietman AL, Bae K, Slater JD, et al: Randomized trial comparing conventional-dose with high-dose conformal radiation therapy in early-stage adenocarcinoma of the prostate: Long-term results from Proton Radiation Oncology Group/American College of Radiology 95-09. J Clin Oncol 28:1106-1111.
20. Alicikus Z.A., Yamada Y., Zhang Z., et al. Ten-year outcomes of high-dose, intensity-modulated radiotherapy for localized prostate cancer. Cancer 2011, 117:1429-1437.
21. Pearson S., Ladapo J., Prosser L. Intensity Modulated Radiation Therapy (IMRT) for Localized Prostate Cancer 2007, Institute for Clinical and Economic Review (ICER), Boston.
22. Lanni T.B., Grills I.S., Kestin L.L., et al. Stereotactic radiotherapy reduces treatment cost while improving overall survival and local control over standard fractionated radiation therapy for medically inoperable non-small-cell lung cancer. Am J Clin Oncol 2011, 34:494-498.
23. Sher D.J., Parikh R., Mays-Jackson S., et al. Cost-effectiveness analysis of SBRT versus IMRT for low-risk prostate cancer. Am J Clin Oncol 2012, [Epub ahead of print on Dec 27, 2012].
24. Hodges J.C., Lotan Y., Boike T.P., et al. Cost-effectiveness analysis of stereotactic body radiation therapy versus intensity-modulated radiation therapy: An emerging initial radiation treatment option for organ-confined prostate cancer. J Oncol Pract 2012, 8:e31s-e317.
25. Parthan A, Pruttivarasin N, Davies D, et al: Comparative cost-effectiveness of stereotactic body radiation therapy versus intensity-modulated and proton radiation therapy for localized prostate cancer. Front Oncol 2:81, 2010.
26. RTOG Clinical Trials Protocol Table. Radiation Therapy Oncology Group. 2013. Available at: Accessed April 20, 2013. http://www.rtog.org/clinicaltrials/protocoltable.aspx.
27. Yu JB: Prostate cancer: Interpreting cost-utility analysis of prostate cancer treatment. Nat Rev Urol 10:129-131, 2013.
28. Timmerman R., Paulus R., Galvin J., et al. Stereotactic body radiation therapy for inoperable early stage lung cancer. J Am Med Assoc 2010, 303:1070-1076.
29. Baumann P., Nyman J., Hoyer M., et al. Outcome in a prospective phase II trial of medically inoperable stage I non-small-cell lung cancer patients treated with stereotactic body radiotherapy. J Clin Oncol 2009, 27:3290-3296.
30. Hypofractionated radiotherapy (stereotactic) versus conventional radiotherapy for inoperable early stage I non-small cell lung cancer (NSCLC) (CHISEL) Clinicaltrials.gov: A Service of the US National Institutes of Health, 2009. Available at: Accessed April 29, 2013. http://clinicaltrials.gov/ct2/show/NCT01014130.
31. Trial of either surgery or stereotactic radiotherapy for early stage (IA) lung cancer (ROSEL). ClinicalTrials.Gov: A Service of the US National Institutes of Health, 2011 Available at: Accessed April 29, 2013. http://clinicaltrials.gov/ct2/show/NCT00687986.
32. Randomized study to compare CyberKnife to surgical resection in stage I non-small cell lung cancer (STARS). ClinicalTrials.Gov: A Service of the US National Institutes of Health, 2013. Available at: Accessed April 29, 2013. http://clinicaltrials.gov/ct2/show/NCT00840749.
33. Palma D., Visser O., Lagerwaard F.J., et al. Impact of introducing stereotactic lung radiotherapy for elderly patients with stage I non-small-cell lung cancer: A population-based time-trend analysis. J Clin Oncol 2010, 28:5153-5159.
34. Pan H., Simpson D.R., Mell L.K., et al. A survey of stereotactic body radiotherapy use in the United States. Cancer 2011, 117:4566-4572.
35. Grills I.S., Mangona V.S., Welsh R., et al. Outcomes after stereotactic lung radiotherapy or wedge resection for stage I non-small-cell lung cancer. J Clin Oncol 2010, 28:928-935.
36. Timmerman R.D. Surgery versus stereotactic body radiation therapy for early-stage lung cancer: Who's down for the count?. J Clin Oncol 2010, 28:907-909.
37. Kavanagh B.D., Miften M., Rabinovitch R.A. Advances in treatment techniques: Stereotactic body radiation therapy and the spread of hypofractionation. Cancer J 2011, 17:177-181.
38. Lievens Y. Hypofractionated breast radiotherapy: Financial and economic consequences. Breast 2010, 19:192-197.
39. Aneja S., Smith B.D., Gross C.P., et al. Geographic analysis of the radiation oncology workforce. Int J Radiat Oncol Biol Phys 2011, 82:1723-1729.
40. Ritter M. Rationale, conduct, and outcome using hypofractionated radiotherapy in prostate cancer. Semin Radiat Oncol 2008, 18:249-256.
41. Macias V., Biete A. Hypofractionated radiotherapy for localised prostate cancer. Review of clinical trials. Clin Transl Oncol 2009, 11:437-445.
42. Quon H., Cheung P.C., Andrew Loblaw D., et al. Quality of life after hypofractionated concomitant intensity-modulated radiotherapy boost for high-risk prostate cancer. Int J Radiat Oncol Biol Phys 2011, 83:617-623.
43. Yeoh E.E., Botten R.J., Butters J., et al. Hypofractionated versus conventionally fractionated radiotherapy for prostate carcinoma: Final results of phase III randomized trial. Int J Radiat Oncol Biol Phys 2011, 81:1271-1278.
44. Kwok Y., Yovino S. Update on radiation-based therapies for prostate cancer. Curr Opin Oncol 2010, 22:257-262.
45. Arcangeli G., Saracino B., Gomellini S., et al. A prospective phase III randomized trial of hypofractionation versus conventional fractionation in patients with high-risk prostate cancer. Int J Radiat Oncol Biol Phys 2010, 78:11-18.
46. Galalae R.M., Martinez A., Nuernberg N., et al. Hypofractionated conformal HDR brachytherapy in hormone naive men with localized prostate cancer. Is escalation to very high biologically equivalent dose beneficial in all prognostic risk groups?. Strahlenther Onkol 2006, 182:135-141.
47. Pollack A., Hanlon A.L., Horwitz E.M., et al. Dosimetry and preliminary acute toxicity in the first 100 men treated for prostate cancer on a randomized hypofractionation dose escalation trial. Int J Radiat Oncol Biol Phys 2006, 64:518-526.
48. Yeoh E.E., Holloway R.H., Fraser R.J., et al. Hypofractionated versus conventionally fractionated radiation therapy for prostate carcinoma: Updated results of a phase III randomized trial. Int J Radiat Oncol Biol Phys 2006, 66:1072-1083.
49. Lukka H., Hayter C., Julian J.A., et al. Randomized trial comparing two fractionation schedules for patients with localized prostate cancer. J Clin Oncol 2005, 23:6132-6138.
50. Dwyer P., Hickey B., Burmeister E., et al. Hypofractionated whole-breast radiotherapy: Impact on departmental waiting times and cost. J Med Imaging Radiat Oncol 2010, 54:229-234.
51. Yarnold J., Bentzen S.M., Coles C., et al. Hypofractionated whole-breast radiotherapy for women with early breast cancer: Myths and realities. Int J Radiat Oncol Biol Phys 2011, 79:1-9.
52. Whelan T.J., Pignol J.P., Levine M.N., et al. Long-term results of hypofractionated radiation therapy for breast cancer. N Engl J Med 2010, 362:513-520.
53. Suh W.W., Pierce L.J., Vicini F.A., et al. A cost comparison analysis of partial versus whole-breast irradiation after breast-conserving surgery for early-stage breast cancer. Int J Radiat Oncol Biol Phys 2005, 62:790-796.
54. Bentzen S.M., Agrawal R.K., Aird E.G., et al. The UK Standardisation of Breast Radiotherapy (START) Trial A of radiotherapy hypofractionation for treatment of early breast cancer: A randomised trial. Lancet Oncol 2008, 9:331-341.
55. Bentzen S.M., Agrawal R.K., Aird E.G., et al. The UK Standardisation of Breast Radiotherapy (START) Trial B of radiotherapy hypofractionation for treatment of early breast cancer: A randomised trial. Lancet 2008, 371:1098-1107.
56. Haviland J.S., Yarnold J.R., Bentzen S.M. Hypofractionated radiotherapy for breast cancer. N Engl J Med 2010, 362:1843. ([author reply 1843-1844]).
57. James ML, Lehman M, Hider PN, et al: Fraction size in radiation treatment for breast conservation in early breast cancer. Cochrane Database Syst Rev [CD003860], 2010.
58. Coles C.E., Brunt A.M., Wheatley D., et al. Breast radiotherapy: Less is more?. Clin Oncol 2013, 25:127-134.
59. Plataniotis G.A., Kouvaris J.R., Dardoufas C., et al. A short radiotherapy course for locally advanced non-small cell lung cancer (NSCLC): Effective palliation and patients' convenience. Lung Cancer 2002, 35:203-207.
60. van den Hout W.B., Kramer G.W., Noordijk E.M., et al. Cost-utility analysis of short- versus long-course palliative radiotherapy in patients with non-small-cell lung cancer. J Natl Cancer Inst 2006, 98:1786-1794.
61. Tang J.I., Shakespeare T.P., Lu J.J., et al. Patients' preference for radiotherapy fractionation schedule in the palliation of symptomatic unresectable lung cancer. J Med Imaging Radiat Oncol 2008, 52:497-502.
62. Hoskin P.J., Bownes P. Innovative technologies in radiation therapy: Brachytherapy. Semin Radiat Oncol 2006, 16:209-217.
63. Bannuru R.R., Dvorak T., Obadan N., et al. Comparative evaluation of radiation treatments for clinically localized prostate cancer: An updated systematic review. Ann Intern Med 2011, 155:171-178.
64. D'Amico A.V., Whittington R., Malkowicz S.B., et al. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. J Am Med Assoc 1998, 280:969-974.
65. Zelefsky M.J., Wallner K.E., Ling C.C., et al. Comparison of the 5-year outcome and morbidity of three-dimensional conformal radiotherapy versus transperineal permanent iodine-125 implantation for early-stage prostatic cancer. J Clin Oncol 1999, 17:517-522.
66. Gore J.L., Kwan L., Lee S.P., et al. Survivorship beyond convalescence: 48-Month quality-of-life outcomes after treatment for localized prostate cancer. J Natl Cancer Inst 2009, 101:888-892.
67. Sanda M.G., Dunn R.L., Michalski J., et al. Quality of life and satisfaction with outcome among prostate-cancer survivors. N Engl J Med 2008, 358:1250-1261.
68. Chen R.C., Clark J.A., Talcott J.A. Individualizing quality-of-life outcomes reporting: How localized prostate cancer treatments affect patients with different levels of baseline urinary, bowel, and sexual function. J Clin Oncol 2009, 27:3916-3922.
69. Marcus D.M., Jani A.B., Godette K., et al. A review of low-dose-rate prostate brachytherapy-Techniques and outcomes. J Natl Med Assoc 2010, 102:500-510.
70. Njeh C.F., Saunders M.W., Langton C.M. Accelerated partial breast irradiation (APBI): A review of available techniques. Radiat Oncol 2010, 5:90.
71. Antonucci J.V., Wallace M., Goldstein N.S., et al. Differences in patterns of failure in patients treated with accelerated partial breast irradiation versus whole-breast irradiation: A matched-pair analysis with 10-year follow-up. Int J Radiat Oncol Biol Phys 2009, 74:447-452.
72. Strnad V., Hildebrandt G., Potter R., et al. Accelerated partial breast irradiation: 5-Year results of the German-Austrian multicenter phase II trial using interstitial multicatheter brachytherapy alone after breast-conserving surgery. Int J Radiat Oncol Biol Phys 2011, 80:17-24.
73. Vicini F., Beitsch P.D., Quiet C.A., et al. Three-year analysis of treatment efficacy, cosmesis, and toxicity by the American Society of Breast Surgeons MammoSite Breast Brachytherapy Registry Trial in patients treated with accelerated partial breast irradiation (APBI). Cancer 2008, 112:758-766.
74. Smith G.L., Xu Y., Buchholz T.A., et al. Association between treatment with brachytherapy vs whole-breast irradiation and subsequent mastectomy, complications, and survival among older women with invasive breast cancer. J Am Med Assoc 2012, 307:1827-1837.
75. Presley C.J., Soulos P.R., Herrin J., et al. Patterns of use and short-term complications of breast brachytherapy in the national medicare population from 2008-2009. J Clin Oncol 2012, 30:4302-4307.
76. Shah C., Lanni T.B., Saini H., et al. Cost-efficacy of acceleration partial-breast irradiation compared with whole-breast irradiation. Breast Cancer Res Treat 2013, 138:127-135.